Lupus Erythematosus Clinical Trial
Official title:
Prognosis Assessment of the Increase of GADD34 Gene Expression for Patient Suffering From Systemic Lupus Erythematosus
Given that GADD34 has been described as a potential key regulator of pro-inflammatory cytokine production in human and elevated blood marker in SLE patients, this study aim to prove that the GADD34 RNA level in mononuclear blood cells can be used as a prognostic marker to assess the risk of SLE flare.
Systemic lupus erythematosus (SLE) has a prevalence estimated between 1 and 6 per 10000
individuals and concerns over 30 000 patients in France for example. As of today, there isn't
any reliable specific blood analysis that can be used to assess the prognosis of SLE, that
means predict a SLE flare. The discovery of such a blood test could allow a better patients'
monitoring in order to help doctors to better adapt treatments (lowering background
treatments when they are not needed and increase them ahead of a potential flare when the
risk assessment raises).
In SLE patients, a recent study shows elevated levels of GADD34 RNA in mononuclear blood
cells : higher than twice the control levels for 36 of the 60 SLE patients and ten times
higher than the control levels for 13 of the 60 SLE patients.
Given that GADD34 has been described as a potential key regulator of pro-inflammatory
cytokine production in human and elevated blood marker in SLE patients, this study aim to
prove that the GADD34 RNA level in mononuclear blood cells can be used as a prognostic marker
to assess the risk of SLE flare.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03543839 -
Trial of Belimumab in Early Lupus
|
Phase 4 | |
| Terminated |
NCT02080195 -
Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)
|
Phase 1/Phase 2 | |
| Completed |
NCT03098823 -
A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE
|
Phase 4 | |
| Recruiting |
NCT03562065 -
Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05545839 -
Transition to Adulthood Through Coaching and Empowerment in Rheumatology
|
N/A | |
| Completed |
NCT05098600 -
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
|
||
| Completed |
NCT04128579 -
Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
|
Phase 1 | |
| Recruiting |
NCT06161363 -
Description of Compliance With Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus
|
||
| Completed |
NCT03421184 -
Dietary Phytoestrogens as Risk Factors for Systemic Lupus Erythematosus
|
N/A | |
| Not yet recruiting |
NCT02891213 -
Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.
|
N/A | |
| Completed |
NCT01686555 -
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
|
Phase 1 | |
| Active, not recruiting |
NCT04018222 -
Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic
|
||
| Completed |
NCT02747277 -
Analysis of B Cells From Autoimmune Individuals
|
||
| Recruiting |
NCT04213690 -
A Pilot Study to Explore the Role of Gut Flora in Lupus
|
||
| Recruiting |
NCT03913754 -
Psycho-social Consequences of Systemic Lupus Erythematosus
|
||
| Recruiting |
NCT06072287 -
The Living With a Long-Term Condition Study
|
||
| Completed |
NCT04089930 -
Long-term Immunogenicity of a Live Herpes Zoster Vaccine in Systemic Lupus Erythematosus (SLE) Patients
|
||
| Completed |
NCT05945784 -
Exploring Accessible Beauty for Individuals With Upper Extremity Deficits
|
||
| Completed |
NCT03253666 -
Nurses' Health Study and Health Professionals Follow-Up Study (Dermatological Component)
|
||
| Recruiting |
NCT01266915 -
Cutaneous Lupus Registry
|